Skip to main content

DaVita Value Stock - Dividend - Research Selection

Davita

ISIN: US23918K1088 , WKN: 897914

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company operates DaVita Rx, a pharmacy that provides oral medications and medication management services to patients with ESRD; disease management services; vascular access services; clinical research programs; physician services; and direct primary care services. As of December 31, 2017, it provided dialysis and administrative services in the United States through a network of 2,510 outpatient dialysis centers serving approximately 197,800 patients; and operated 237 outpatient dialysis centers located in 11 countries outside of the United States. Further, the company provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was founded in 1994 and is headquartered in Denver, Colorado.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


DaVita : 2025 Annual Report (investors annual report 2025)

2026-05-04
Annual Report 2025 Dear Stakeholders, As we reflect on 2025, we're grateful for the strength, agility, and dedication of our caregivers. In a...

DaVita : Proxy Statement (investors proxy statement 2026)

2026-05-04
Notice of 2026 Annual Meeting and Proxy Statement ...

DaVita (DVA) Q1 Earnings: What To Expect

2026-05-04
Dialysis provider DaVita Inc. (NYSE:DVA) will be reporting results this Tuesday after market hours. Here’s what you need to know.

Can Execution and Volume Trends Support DaVita's Q1 Earnings?

2026-05-01
DVA's first-quarter 2026 results may face seasonal volume and RPT headwinds, but cost discipline, reimbursement growth and IKC contributions could aid results.

Here is What to Know Beyond Why DaVita Inc. (DVA) is a Trending Stock

2026-05-01
DaVita HealthCare (DVA) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Encompass Health (EHC) Q1 Earnings and Revenues Surpass Estimates

2026-04-30
Encompass Health (EHC) delivered earnings and revenue surprises of +6.14% and +0.93%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

DaVita HealthCare (DVA) Ascends While Market Falls: Some Facts to Note

2026-04-29
In the latest trading session, DaVita HealthCare (DVA) closed at $151.99, marking a +1.28% move from the previous day.

How Analyst Model Shifts Are Rewriting The DaVita (DVA) Investment Narrative

2026-04-29
DaVita’s latest analyst update keeps the fair value estimate steady at US$151.71, while several firms are lifting their individual price targets by US$4 to US$30. Those higher targets are being framed around refreshed models, as analysts reassess upside and risk based on shared assumptions and recent research. As you read on, you will see how these shifting targets can help you track the story the market is building around DaVita over time. Analyst Price Targets don't always capture the full...

3 Reasons DVA is Risky and 1 Stock to Buy Instead

2026-04-27
DaVita has had an impressive run over the past six months as its shares have beaten the S&P 500 by 12.5%. The stock now trades at $150.12, marking a 15.9% gain. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.

What’s So Good About DaVita (DVA) That Warren Buffett Remains Bullish On It Since 15 Years?

2026-04-23
DaVita Inc. (NYSE:DVA) is included in our list of the best Warren Buffett stocks. Buffett added DaVita Inc. (NYSE:DVA) to his portfolio in 2011, purchasing 5.37 million shares worth $203.51 million, which made the stock Warren Buffett’s 20th biggest holding as of Q4 2011. Berkshire’s investment in the stock has grown to $3.61 billion as of […]